


P3.264: Multicentre retrospective study on efficacy and safety of novel EGFR-TKIs in advanced EGFR ex20ins NSCLC (CTONG 2401 study)



IASLC 2026 World
Conference on Lung Cancer

SEPTEMBER 12 – 15, 2026
SEOUL, REPUBLIC OF KOREA

Jin Zhou¹, Yi-Chen Zhang², Long-Feng Zhang³, Yi-Quan Xu³, Ke-Jun Liu⁴, Yang Xia⁵, Chang Lu², Yuan Xun⁶, Long Huang⁷, Yi-Hui Yao⁸, Zi-Ming Li⁹, Yu-Kun Kuang¹⁰, Jin-Xun Wu¹¹, Dong-Mei Yuan¹², Dan Pu¹³, He-Ming Li¹⁴, Ting-Ting Yu¹⁵, Xuan Hong¹⁶, Wei Song¹⁷, Liang Zhang¹⁸, He-Lei Hou¹⁹, Ying-Long Peng², Molly Siu Ching Li²⁰, Si-Yang Maggie Liu²

1.Department of Oncology, Sichuan Cancer Hospital, Chengdu/CN, 2.Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou/CN, 3.Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou/CN, 4.Dongguan Institute of Clinical Cancer Research, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University, Dongguan/CN, 5.Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou/CN, 6.Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan/CN, 7.Department of Lung Cancer Center, The Second Affiliated Hospital of Nanchang University, Nanchang/CN, 8.Department of Oncology, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology), The Second Clinical Medical College, Jinan University, Shenzhen/CN, 9.Department of Oncology, Shanghai Chest Hospital/Affiliated Changhai Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai/CN, 10.Division of Pulmonary and Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou/CN, 11.Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen/CN, 12.Department of Respiratory and Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing/CN, 13.Lung Cancer Center, West China Hospital, Sichuan University, Chengdu/CN, 14.Department of Oncology, The First Hospital of China Medical University, Shenyang/CN, 15.Department of Pulmonary Medicine, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi/CN, 16.The First Department of Respiratory Medicine, Affiliated Tumor Hospital of Harbin Medical University, Harbin/CN, 17.Department of Oncology, The First Hospital of Jilin University, Changchun/CN, 18.Jilin Cancer Hospital, Changchun/CN, 19.Department of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao/CN, 20.State Key Laboratory of Translational Oncology, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong/CN, 21.Department of Thoracic Cancer, Liaoning Cancer Hospital, Shenyang 110801, China. 7.Department of Oncology, Henan Provincial People's Hospital, Zhengzhou 450003, China. 8.Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

INTRODUCTION

- EGFR exon 20 insertions (ex20ins) accounts for approximately 10% of EGFR mutation positive NSCLC. Recently, both sunvozertinib and firmonertinib have demonstrated clinical activity in advanced EGFR ex20ins NSCLC in single-arm clinical trials. However, their real-world efficacy and safety, including intracranial efficacy and impact of ex20ins subtype on treatment outcomes, remain unclear. We conducted a real-world study to address these questions.

METHODS

- This multicentre retrospective study enrolled patients with advanced EGFR ex20ins NSCLC treated with either sunvozertinib or firmonertinib. Clinical data was collected by chart review. Efficacy endpoints included objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). Exploratory endpoints include intracranial efficacy, impact of treatment line (first-line [1L] versus second- or later lines [2+L]) and EGFR ex20ins subtype on TKI efficacy. Safety endpoints included incidence of treatment-related adverse events (AEs), dose interruption, reduction and discontinuation.

RESULTS

Patient Characteristics


- A total of 304 patients were enrolled from 21 centres from China between 07/01/2021 and 11/20/2025. Median age was 60 years (range 24-90), 170 (56.1%) were female. 89 patients received prior chemotherapy prior to TKI, while no patients received prior amivantamab.

Efficacy of Sunvozertinib

- 195 patients received sunvozertinib, with a median follow up was 7.5 months. ORR, and median PFS were 33.3% and 7.9 months (95% CI 5.4 – 10.4), respectively. The median OS was not reached.
- In the 1L (n=45) and 2+L (n=70) setting, sunvozertinib achieved ORR/median PFS of 55.6%/9.7 months and 18.2%/6.9 months, respectively. Among 25 patients with brain metastases evaluable for response, 6 (24.0%) achieved an intracranial response.

Efficacy of Furmonertinib

- 109 patients received furmonertinib, with a median follow up was 16.7 months. ORR, and median PFS were 25.8% and 11.0 months (95% CI 7.8 – 14.2), respectively. The median OS was not reached. In the 1L (n=52) and 2+L (n=32) setting, furmonertinib achieved ORR/median PFS of 34.0%/11.3 months and 13.3%/9.8 months, respectively. Among 16 patients with brain metastases evaluable for response, 3 (18.8%) achieved an intracranial response.
- The adverse events were still on summarization.



CONCLUSION

- This represents the largest real-world dataset on patients with advanced EGFR ex20ins NSCLC treated with novel EGFR ex20ins active TKIs. We confirm the clinical activity of sunvozertinib and furmonertinib across different treatment lines, providing valuable evidence to support their clinical application in this population.

ACKNOWLEDGEMENTS

- The authors thank the participants and their caregivers, the investigators, and all the site staff who have been and are participating in this study, as well as Innovent Biologics Inc., for their dedicated support.